Amneal Pharmaceuticals has launched budesonide capsules, 3 mg, an AB-rated equivalent to Entocort EC.
Annual U.S. sales of budesonide and its generic equivalents were $187 million, according to November 2017 IQVIA market data. Budesonide capsules are now shipping to wholesalers, distributors and direct to the trade.
Budesonide is the first product launch of the new year for Amneal Pharmaceuticals. In 2017, the company received 45 ANDA approvals (39 final and 6 tentative) and launched 35 product families—nine of these by its injectables subsidiary Amneal Biosciences.